Success Stories: NAILG Helps an Indian Scientist Achieve NIW Approval for Tackling Medication Safety Challenges

Client’s Testimonial:

“I am very grateful for your assistance throughout this process.”

On January 29^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist-I in the Field of Medicinal Chemistry (Approval Notice).

General Field: Medicinal Chemistry

Position at the Time of Filing: Scientist-I

Country of Origin: India

State of Residence at the Time of Filing: Wisconsin

Approval Notice Date: January 29^th, 2025

Processing Time: 3 months, 4 days (Premium Processing Requested)

Case Summary:

Every year, millions of patients suffer from preventable harm caused by unsafe or ineffective medications. Our client, a medicinal chemistry expert, has dedicated his career to solving this problem. His research into drug design and optimization has now been recognized by USCIS with the approval of his EB-2 NIW (National Interest Waiver) petition, prepared by North America Immigration Law Group (NAILG).

Research with Substantial Merit and National Importance:
After carefully reviewing his credentials, NAILG recognized him as a strong candidate for the NIW category. His proposed endeavor, to investigate the design, synthesis, optimization, and characterization of small molecule compounds, addresses urgent national healthcare challenges. With drug-resistant infections causing tens of thousands of deaths annually in the U.S. and costing billions in treatment expenses, his work directly supports national efforts to enhance drug safety, reduce healthcare costs, and sustain America’s leadership in pharmaceutical innovation.

Well Positioned to Advance the Proposed Endeavor:
Our client’s strong academic and professional background, including a Ph.D. in chemical sciences and research appointments at internationally recognized institutions, has prepared him to carry forward this vital work. He has published extensively, with 22 peer-reviewed journal articles, 2 abstracts, 1 granted patent, and 2 patent applications, demonstrating his ability to produce original and impactful research. His publications have been cited 547 times, placing several of his papers among the most highly cited for their publication years.

Beyond authorship, he has also been invited to serve the academic community as a peer reviewer, completing at least 24 reviews for high-profile journals. He has further demonstrated leadership as a guest editor for a special issue on PET imaging, underscoring his recognition as a respected authority in his field.

Due to its clear national importance, our client’s research has been supported with funding from the U.S. Congressionally Directed Medical Research Programs and the National Institute of Allergy and Infectious Diseases.

NIW Approval and Outlook:
Based on his impressive record of original research, sustained international recognition, and proven capacity to advance drug discovery, USCIS approved his NIW petition. One expert summarized the importance of his contributions:

“To conclude, [Client] has advanced the field of medicinal chemistry by applying his extensive knowledge of pharmacophores and prodrugs to improve the safety and efficacy of therapeutic agents and drug development processes. [Client]’s prowess in medicinal chemistry situates him as a leader in the field and establishes his inherent value to the United States.”

With the guidance of the North America Immigration Law Group (NAILG), he has secured approval to continue his critical research. His ongoing work in medicinal chemistry will help shape the future of therapeutic development, strengthening America’s ability to address global health challenges through innovation.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.